2024

Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction
Marius W, Leticia O, Friedrich K, Stephan M, Louisa H, Tabea S, Elisa S, Pauline W, Yi D, Qi M, Barbara S, Carsten B, Walter F, Jasmin W, Franziska B
ONCOIMMUNOLOGY. 2024;13(1):2346359.

2022

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar P, Tsoka S, Bullinger L, Seubert E, Smit D, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W
J IMMUNOTHER CANCER. 2022;10(12):.

2021

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W
INT J MOL SCI. 2021;22(23):.

Letzte Aktualisierung aus dem FIS: 08.09.2025 - 00:34 Uhr